Literature DB >> 23948572

Correlates of protection against influenza infection in humans--on the path to a universal vaccine?

Chris Ka-fai Li1, Rino Rappuoli, Xiao-Ning Xu.   

Abstract

Influenza is an acute respiratory viral infection with high mutation rate and pandemic potential. Vaccination is an effective means of prevention and control of influenza, but the challenges of vaccine mismatches for the next influenza seasons and adequate global supply of influenza vaccines limit its effectiveness. Protective immunity in vaccination or natural infection is primarily mediated by antibody responses against surface proteins of influenza including haemagglutinin (HA) as the major neutralizing target, whereas strong T cell responses to internal viral proteins are associated with reduced disease severity. Recently, identification of broadly neutralizing antibodies against the conserved stem region of HA from influenza infected individuals has invigorated interest in development of a universal vaccine against different subtypes of influenza. Moreover, because of the cross-reactive nature of T cell recognition and more conserved internal antigens of influenza, strategies that boost memory T cell responses to these internal antigens may provide not only help for antibody-mediated protection but also limit the cell damage caused by viral infection directly. This is particularly important in acute infection with new pandemic viruses or antibody-escape variants where there are no pre-existing neutralizing antibodies. Here, we review the protective immune correlates against human influenza infection and discuss current status of universal influenza vaccine development. Crown
Copyright © 2013. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23948572     DOI: 10.1016/j.coi.2013.07.005

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  22 in total

1.  Report on the second WHO integrated meeting on development and clinical trials of influenza vaccines that induce broadly protective and long-lasting immune responses: Geneva, Switzerland, 5-7 May 2014.

Authors:  Nancy J Cox; Julian Hickling; Rebecca Jones; Guus F Rimmelzwaan; Linda C Lambert; John Boslego; Larisa Rudenko; Leena Yeolekar; James S Robertson; Joachim Hombach; Justin R Ortiz
Journal:  Vaccine       Date:  2015-10-23       Impact factor: 3.641

2.  Selection of therapeutic H5N1 monoclonal antibodies following IgVH repertoire analysis in mice.

Authors:  Sean A Gray; Margaret Moore; Emily J VandenEkart; Richard P Roque; Richard A Bowen; Neal Van Hoeven; Steven R Wiley; Christopher H Clegg
Journal:  Antiviral Res       Date:  2016-04-21       Impact factor: 5.970

3.  Activation of the RIG-I pathway during influenza vaccination enhances the germinal center reaction, promotes T follicular helper cell induction, and provides a dose-sparing effect and protective immunity.

Authors:  Raveendra R Kulkarni; Mohammed Ata Ur Rasheed; Siddhartha Kumar Bhaumik; Priya Ranjan; Weiping Cao; Carl Davis; Krishna Marisetti; Sunil Thomas; Shivaprakash Gangappa; Suryaprakash Sambhara; Kaja Murali-Krishna
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

4.  Methylglycol chitosan and a synthetic TLR4 agonist enhance immune responses to influenza vaccine administered sublingually.

Authors:  Justin L Spinner; Hardeep S Oberoi; Yvonne M Yorgensen; Danielle S Poirier; David J Burkhart; Martin Plante; Jay T Evans
Journal:  Vaccine       Date:  2015-09-21       Impact factor: 3.641

Review 5.  Distinguishing Causation From Correlation in the Use of Correlates of Protection to Evaluate and Develop Influenza Vaccines.

Authors:  Wey Wen Lim; Nancy H L Leung; Sheena G Sullivan; Eric J Tchetgen Tchetgen; Benjamin J Cowling
Journal:  Am J Epidemiol       Date:  2020-03-02       Impact factor: 4.897

Review 6.  B-cell responses to HIV infection.

Authors:  Susan Moir; Anthony S Fauci
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

7.  Measuring Influenza Neutralizing Antibody Responses to A(H3N2) Viruses in Human Sera by Microneutralization Assays Using MDCK-SIAT1 Cells.

Authors:  F Liaini Gross; Yaohui Bai; Stacie Jefferson; Crystal Holiday; Min Z Levine
Journal:  J Vis Exp       Date:  2017-11-22       Impact factor: 1.355

8.  A cationic liposome-DNA complexes adjuvant (JVRS-100) enhances the immunogenicity and cross-protective efficacy of pre-pandemic influenza A (H5N1) vaccine in ferrets.

Authors:  Feng Liu; Xiangjie Sun; Jeffery Fairman; David B Lewis; Jacqueline M Katz; Min Levine; Terrence M Tumpey; Xiuhua Lu
Journal:  Virology       Date:  2016-03-21       Impact factor: 3.616

Review 9.  Influenza vaccines: challenges and solutions.

Authors:  Katherine Houser; Kanta Subbarao
Journal:  Cell Host Microbe       Date:  2015-03-11       Impact factor: 21.023

10.  Influenza T-cell epitope-loaded virosomes adjuvanted with CpG as a potential influenza vaccine.

Authors:  Peter C Soema; Sietske K Rosendahl Huber; Geert-Jan Willems; Wim Jiskoot; Gideon F A Kersten; Jean-Pierre Amorij
Journal:  Pharm Res       Date:  2014-10-25       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.